# Korro Bio, Inc.: financial statements, quarterly

KRRO · Nasdaq · CIK 1703647 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/krro.md) · [Financials](/companies/krro/financials.md) · [Filings](/companies/krro/filings.md) · [Insiders](/companies/krro/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/krro/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-065800.md) | [0.0](/filings/0000950170-25-106912.md) | [0.0](/filings/0001193125-25-277572.md) | [2.3 d](/filings/0001193125-26-104156.md) | [2.6](/filings/0001193125-26-210303.md) | [1.5](/filings/0001193125-26-336707.md) | [1.1](/filings/0001193125-25-277572.md) | [1.3 d](/filings/0001193125-26-104156.md) | [0.0](/filings/0001193125-26-210303.md) | [0.0](/filings/0001193125-26-336707.md) |
| Research and development | $m | [14.0](/filings/0000950170-24-125362.md) | [15.4 d](/filings/0000950170-25-040759.md) | [13.6](/filings/0000950170-25-065800.md) | [17.1](/filings/0000950170-25-106912.md) | [16.0](/filings/0001193125-25-277572.md) | [17.0 d](/filings/0001193125-26-104156.md) | [19.7](/filings/0001193125-26-210303.md) | [20.1](/filings/0001193125-26-336707.md) | [13.8](/filings/0001193125-25-277572.md) | [11.0 d](/filings/0001193125-26-104156.md) | [13.0](/filings/0001193125-26-210303.md) | [13.6](/filings/0001193125-26-336707.md) |
| Operating income | $m | [(19.1)](/filings/0000950170-24-125362.md) | [(26.9) d](/filings/0000950170-25-040759.md) | [(21.5)](/filings/0000950170-25-065800.md) | [(24.1)](/filings/0000950170-25-106912.md) | [(23.3)](/filings/0001193125-25-277572.md) | [(23.0) d](/filings/0001193125-26-104156.md) | [(25.0)](/filings/0001193125-26-210303.md) | [(27.2)](/filings/0001193125-26-336707.md) | [(19.2)](/filings/0001193125-25-277572.md) | [(50.4) d](/filings/0001193125-26-104156.md) | [(20.4)](/filings/0001193125-26-210303.md) | [(20.1)](/filings/0001193125-26-336707.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-058171.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-125362.md) | [0.0 d](/filings/0000950170-25-040759.md) | [0.0](/filings/0000950170-25-065800.md) | [0.0](/filings/0000950170-25-106912.md) | [(0.0)](/filings/0001193125-25-277572.md) | [0.1 d](/filings/0001193125-26-104156.md) | [0.0](/filings/0001193125-26-210303.md) | [0.0](/filings/0001193125-26-336707.md) | [0.0](/filings/0001193125-25-277572.md) | [0.6 d](/filings/0001193125-26-104156.md) | [0.1](/filings/0001193125-26-210303.md) | [0.1](/filings/0001193125-26-336707.md) |
| Net income | $m | [(18.5)](/filings/0000950170-24-125362.md) | [(25.4) d](/filings/0000950170-25-040759.md) | [(19.6)](/filings/0001193125-25-277572.md) | [(21.8)](/filings/0001193125-25-277572.md) | [(21.0)](/filings/0001193125-25-277572.md) | [(21.2) d](/filings/0001193125-26-104156.md) | [(23.4)](/filings/0001193125-26-336707.md) | [(25.8)](/filings/0001193125-26-336707.md) | [(18.1)](/filings/0001193125-25-277572.md) | [(50.0) d](/filings/0001193125-26-104156.md) | [(19.6)](/filings/0001193125-26-336707.md) | [(18.9)](/filings/0001193125-26-336707.md) |
| Diluted EPS | $ per share | [(65.08)](/filings/0000950170-24-125362.md) | not reported | [(2.44)](/filings/0000950170-25-065800.md) | [(2.43)](/filings/0000950170-25-106912.md) | [(2.26)](/filings/0001193125-25-277572.md) | not reported | [(2.49)](/filings/0001193125-26-210303.md) | [(2.74)](/filings/0001193125-26-336707.md) | [(1.92)](/filings/0001193125-25-277572.md) | not reported | [(1.69)](/filings/0001193125-26-210303.md) | [(1.07)](/filings/0001193125-26-336707.md) |
| Basic EPS | $ per share | [(65.08)](/filings/0000950170-24-125362.md) | not reported | [(2.44)](/filings/0000950170-25-065800.md) | [(2.43)](/filings/0000950170-25-106912.md) | [(2.26)](/filings/0001193125-25-277572.md) | not reported | [(2.49)](/filings/0001193125-26-210303.md) | [(2.74)](/filings/0001193125-26-336707.md) | [(1.92)](/filings/0001193125-25-277572.md) | not reported | [(1.69)](/filings/0001193125-26-210303.md) | [(1.07)](/filings/0001193125-26-336707.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-11-03) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.6](/filings/0000950170-25-040759.md) | [166](/filings/0000950170-25-040759.md) | [139](/filings/0000950170-24-059493.md) | [91.2](/filings/0000950170-24-096189.md) | [63.2](/filings/0000950170-24-125362.md) | [55.6](/filings/0001193125-26-104156.md) | [64.1](/filings/0000950170-25-065800.md) | [33.6](/filings/0000950170-25-106912.md) | [24.2](/filings/0001193125-25-277572.md) | [21.8](/filings/0001193125-26-336707.md) | [61.7](/filings/0001193125-26-210303.md) | [24.9](/filings/0001193125-26-336707.md) |
| Current assets | $m | not reported | [173](/filings/0000950170-25-040759.md) | [146](/filings/0000950170-24-059493.md) | [164](/filings/0000950170-24-096189.md) | [153](/filings/0000950170-24-125362.md) | [132](/filings/0001193125-26-104156.md) | [121](/filings/0000950170-25-065800.md) | [103](/filings/0000950170-25-106912.md) | [98.2](/filings/0001193125-25-277572.md) | [82.4](/filings/0001193125-26-336707.md) | [120](/filings/0001193125-26-210303.md) | [121](/filings/0001193125-26-336707.md) |
| Total assets | $m | not reported | [222](/filings/0000950170-25-040759.md) | [198](/filings/0000950170-24-059493.md) | [250](/filings/0000950170-24-096189.md) | [244](/filings/0000950170-24-125362.md) | [226](/filings/0001193125-26-104156.md) | [202](/filings/0000950170-25-065800.md) | [180](/filings/0000950170-25-106912.md) | [162](/filings/0001193125-25-277572.md) | [114](/filings/0001193125-26-336707.md) | [184](/filings/0001193125-26-210303.md) | [163](/filings/0001193125-26-336707.md) |
| Current liabilities | $m | not reported | [19.5](/filings/0000950170-25-040759.md) | [11.1](/filings/0000950170-24-059493.md) | [12.3](/filings/0000950170-24-096189.md) | [13.6](/filings/0000950170-24-125362.md) | [15.0](/filings/0001193125-26-104156.md) | [12.9](/filings/0000950170-25-065800.md) | [17.2](/filings/0000950170-25-106912.md) | [14.6](/filings/0001193125-25-277572.md) | [11.9](/filings/0001193125-26-336707.md) | [14.8](/filings/0001193125-26-210303.md) | [12.6](/filings/0001193125-26-336707.md) |
| Total liabilities | $m | not reported | [51.8](/filings/0000950170-25-040759.md) | [46.6](/filings/0000950170-24-059493.md) | [51.5](/filings/0000950170-24-096189.md) | [63.9](/filings/0000950170-24-125362.md) | [65.8](/filings/0001193125-26-104156.md) | [63.3](/filings/0000950170-25-065800.md) | [65.3](/filings/0000950170-25-106912.md) | [62.5](/filings/0001193125-25-277572.md) | [62.1](/filings/0001193125-26-336707.md) | [64.0](/filings/0001193125-26-210303.md) | [60.2](/filings/0001193125-26-336707.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | not reported | [170](/filings/0001193125-26-104156.md) | [151](/filings/0001193125-25-277572.md) | [198](/filings/0001193125-25-277572.md) | [180](/filings/0001193125-25-277572.md) | [160](/filings/0001193125-26-336707.md) | [139](/filings/0001193125-26-336707.md) | [115](/filings/0001193125-26-336707.md) | [99.0](/filings/0001193125-25-277572.md) | [51.4](/filings/0001193125-26-336707.md) | [120](/filings/0001193125-26-336707.md) | [103](/filings/0001193125-26-336707.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.8) d](/filings/0000950170-24-125362.md) | [(21.1) d](/filings/0000950170-25-040759.md) | [(21.9)](/filings/0000950170-25-065800.md) | [(14.6) d](/filings/0000950170-25-106912.md) | [(16.1) d](/filings/0001193125-25-277572.md) | [(7.5) d](/filings/0001193125-26-104156.md) | [(24.5)](/filings/0001193125-26-210303.md) | [(19.2) d](/filings/0001193125-26-336707.md) | [(17.2) d](/filings/0001193125-25-277572.md) | [(17.7) d](/filings/0001193125-26-104156.md) | [(16.1)](/filings/0001193125-26-210303.md) | [(17.0) d](/filings/0001193125-26-336707.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125362.md) | [1.7 d](/filings/0000950170-25-040759.md) | [5.6](/filings/0000950170-25-065800.md) | [6.0 d](/filings/0000950170-25-106912.md) | [4.9 d](/filings/0001193125-25-277572.md) | [1.5 d](/filings/0001193125-26-104156.md) | [0.1](/filings/0001193125-26-210303.md) | [0.1 d](/filings/0001193125-26-336707.md) | [0.2 d](/filings/0001193125-25-277572.md) | [0.1 d](/filings/0001193125-26-104156.md) | [0.0](/filings/0001193125-26-210303.md) | [0.0 d](/filings/0001193125-26-336707.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.2](/filings/0000950170-23-058171.md) | [0.3](/filings/0000950170-24-059493.md) | [0.3](/filings/0000950170-24-096189.md) | [0.3](/filings/0000950170-24-125362.md) | [8.0](/filings/0000950170-25-065800.md) | [9.0](/filings/0000950170-25-106912.md) | [9.3](/filings/0001193125-25-277572.md) | [9.4](/filings/0001193125-26-210303.md) | [9.4](/filings/0001193125-26-336707.md) | [9.4](/filings/0001193125-25-277572.md) | [11.6](/filings/0001193125-26-210303.md) | [17.6](/filings/0001193125-26-336707.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,725,646 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336707.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.